Publicité
Publicité
ACRV
Acrivon Therapeutics, Inc. Common Stock
1.77
USDSponsorisé
-0.16
-8.50%
09 janv., 15:59 UTC -5
Fermé
Après-marché
1.72
-0.05
-2.60%
ACRV Rapports sur les bénéfices
Ratio de surprise positive
ACRV a dépassé 10 des 12 dernières estimations.
83%
Prochain rapport
Date du prochain rapport
24 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
$197.20K
/-$0.48
Variation implicite de Q3 25 (Revenue/ EPS)
--
/+2.13%
Variation implicite de Q4 24 (Revenue/ EPS)
--
/-20.00%
Acrivon Therapeutics, Inc. Common Stock earnings per share and revenue
On 13 nov. 2025, ACRV reported earnings of -0.47 USD per share (EPS) for Q3 25, beating the estimate of -0.60 USD, resulting in a 21.90% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +8.21% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analystes forecast an EPS of -0.48 USD, with revenue projected to reach 197.20 mille USD, implying an hausse of 2.13% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Acrivon Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Acrivon Therapeutics, Inc. Common Stock reported EPS of -$0.47, beating estimates by 21.9%, and revenue of $0.00, 0% as expectations.
How did the market react to Acrivon Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 8.21%, changed from $2.07 before the earnings release to $2.24 the day after.
When is Acrivon Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 24 mars 2026.
What are the forecasts for Acrivon Therapeutics, Inc. Common Stock's next earnings report?
Based on 10
analystes, Acrivon Therapeutics, Inc. Common Stock is expected to report EPS of -$0.48 and revenue of $197.20K for Q4 2025.
Which companies are reporting earnings today?
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité